Fig 4.

Association between intraoperative morphine milligram equivalents (MMEs) and oncogenic pathway alterations in patients with lung adenocarcinoma. (A) OncoPrint of alteration frequencies of 10 canonical oncogenic pathways for the overall study cohort. Patients are subdivided by pathologic tumour stage. (B) Five-year predicted recurrence-specific survival (RSS) for patients with altered and unaltered Wnt and Hippo pathways. (C) Comparative bar graphs representing the alteration rate for each oncologic signalling pathway by stage. (D) Co-occurrence and mutual exclusivity between oncogenic pathways across all tumours. FGA, fraction genome altered; TMB, tumour mutational burden; WT, wild-type.